Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2051-1426
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations ; volume:7 ; number:1 ; day:29 ; month:3 ; year:2019 ; pages:1-8 ; date:12.2019
Journal for ImmunoTherapy of Cancer ; 7, Heft 1 (29.3.2019), 1-8, 12.2019
- Urheber
-
Ascierto, Paolo A.
Capone, Mariaelena
Grimaldi, Antonio M.
Mallardo, Domenico
Simeone, Ester
Madonna, Gabriele
Roder, Heinrich
Meyer, Krista
Asmellash, Senait
Oliveira, Carlos
Roder, Joanna
Grigorieva, Julia
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s40425-019-0569-1
- URN
-
urn:nbn:de:101:1-2019042020060839922338
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:50 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Ascierto, Paolo A.
- Capone, Mariaelena
- Grimaldi, Antonio M.
- Mallardo, Domenico
- Simeone, Ester
- Madonna, Gabriele
- Roder, Heinrich
- Meyer, Krista
- Asmellash, Senait
- Oliveira, Carlos
- Roder, Joanna
- Grigorieva, Julia
- SpringerLink (Online service)
Ähnliche Objekte (12)
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
The role of BRAF V600 mutation in melanoma
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
The role of BRAF V600 mutation in melanoma
Systematic review of the use of granulocyte–macrophage colony-stimulating factor in patients with advanced melanoma
Checkpoint inhibitors in melanoma and early phase development in solid tumors: what’s the future?
Adjuvant therapy of melanoma with interferon: lessons of the past decade
Melanoma: the role of surgery in the era of new therapies
What have we learned from cancer immunotherapy in the last 3 years?
Combination therapy: the next opportunity and challenge of medicine
Melanoma: A model for testing new agents in combination therapies
Anti-CTLA4 monoclonal antibodies: the past and the future in clinical application
Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use
Effect of dabrafenib on melanoma cell lines harbouring the BRAF V600D/R mutations
Highlights and summary of the 28th annual meeting of the Society for Immunotherapy of Cancer
The role of BRAF V600 mutation in melanoma